Madrid

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Asthma1 trial
• COPD1 trial
• Head and neck cancer1 trial
• Lung cancer1 trial
• Multiple sclerosis1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 41 trial

Status

• Active, not recruiting2 trials
• Completed2 trials
• Terminated2 trials
• Recruiting1 trial

Lead sponsor

• Sanofi7 trials

Running trials

• Recruiting

  Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  NCT07190222· Phase 3· Sanofi· Source

• Active, not recruiting

  SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

  NCT05405166· Phase 3· Sanofi· Source

• Active, not recruiting

  Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

  NCT04270409· Phase 3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Terminated

  A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

  NCT05061420· Phase 2· Sanofi· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Terminated

  Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

  NCT04394624· Phase 2· Sanofi· Source

• Completed

  A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

  NCT04502862· Phase 4· Sanofi· Source